The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1291
July 28, 2008
View Complete Issue         Table of Contents 2019 
Duloxetine (Cymbalta) for Fibromyalgia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Duloxetine (Cymbalta) for Fibromyalgia
July 28, 2008 (Issue: 1291)
Duloxetine (Cymbalta - Lilly) is the second drug to be approved by the FDA for treatment of fibromyalgia. Pregabalin (Lyrica), which is also approved for treatment of neuropathic pain and epilepsy, was the first. Duloxetine is a selective serotonin...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Duloxetine (Cymbalta) for Fibromyalgia
Article code: 1291a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.